ResultsReply to Clarification- Financial results
The company clarified errors in its financial results, revising XBRL filings.
BALAXI PHARMACEUTICALS LIMITEDBALAXI · Filed with the exchange
Standalone total expenses were adjusted by 0.20 Cr.
Crucially, consolidated other comprehensive income for the latest quarter and fiscal year was corrected from negative to positive, significantly impacting total comprehensive income.
No comments yet. Be the first.